Edwards Lifesciences Corporation (EW) Stock: Price, Forecast & Analyst Target
Edwards Lifesciences Corporation (EW) — MoonshotScore 93/100 (Exceptional band), calculated Nov 18, 2026. Price $105.23 (-0.19%), as of the Nov 18, 2026 trading session; market cap $60.5B. Expected results Feb 9, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Edwards Lifesciences Corporation · EW · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Edwards Lifesciences is a focused structural-heart device company whose revenue is led by transcatheter heart valves, with surgical valves and mitral and tricuspid therapies forming the rest of the reported segment mix. The case depends on whether newer catheter-based therapies can broaden growth while the dominant valve franchise and strong balance sheet continue funding heavy research and commercial investment.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Edwards Lifesciences (EW)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- expected results Feb 9, 2027
- Altman Z 14.22 · Piotroski F 8
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $105.23 | |
| Change on the day | -0.19% | |
| 52-week range | $74.66–$108.00 | |
| Market capitalisation | $60.5B | — |
| Price / earnings (trailing) | 59.56 | |
| Shares traded on the day | 3.92M | |
| Beta (volatility vs the S&P 500) | 0.83 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Edwards Lifesciences (EW): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Edwards Lifesciences (EW), and what does it report?
Short answer · as of
Edwards sells replacement and repair technologies used by hospitals to treat structural heart disease, including minimally invasive valve systems, surgical tissue valves, and PASCAL and Cardioband therapies for mitral and tricuspid disease.
Research dated 2026-09-12.
It reaches healthcare providers through its own sales force and independent distributors, so demand ultimately reflects procedure adoption rather than consumer purchasing.
Reported revenue is concentrated in transcatheter heart valves, with surgical heart valve therapy and transcatheter mitral and tricuspid therapies presented separately. Edwards is therefore better understood as a portfolio of valve-procedure franchises than as a general medical-device supplier.
What do the latest results show for Edwards Lifesciences (EW)?
Research dated 2026-09-12.
Revenue, gross profit and operating profit rose from the preceding period, but net income and diluted earnings fell. Higher research and selling, general and administrative spending absorbed most of the gross-profit increase, while the latest earnings release still exceeded estimates for revenue and earnings.
Management separately warned that foreign exchange flowing through hedges should keep gross margin near the low end of its prior range. It nevertheless expects operating margin near the high end of prior guidance, implying that expense discipline and mix must offset the gross-margin drag if that outlook is to hold.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.72B Nov 4, 2026
- Latest report · revenue estimate
- $1.68B Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $1.72B | $1.68B | $0.8000 | $0.7440 |
| Jul 23, 2026 | $1.74B | $1.70B | $0.7800 | $0.7430 |
| Apr 23, 2026 | $1.65B | $1.60B | $0.7800 | $0.7290 |
| Feb 10, 2026 | $1.57B | $1.55B | $0.5800 | $0.6180 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.55B | $291M | $0.50 (diluted) |
| Q4 FY2025 | $1.57B | $91M | $0.16 (diluted) |
| Q1 FY2026 | $1.65B | $381M | $0.66 (diluted) |
| Q2 FY2026 | $1.74B | $242M | $0.42 (diluted) |
What are the financial strengths and risks for Edwards Lifesciences (EW)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and short-term investments exceed total debt by a wide margin, liquidity ratios are high, and the distress screen indicates ample financial capacity. Operating cash flow has been positive throughout most of the recent series despite pronounced swings, and the latest inflow comfortably covered capital spending.
The operating risk is concentration, not near-term financing: transcatheter heart valves provide most reported segment revenue. A slowdown in procedures or adoption within that franchise would land on the largest revenue pool, while foreign-exchange pressure is already present in management’s margin outlook.
What should you watch next at Edwards Lifesciences (EW)?
Short answer · as of
The next earnings report is expected on Feb 9, 2027.
Research dated 2026-09-12.
PASCAL is the clearest near-term operating marker. Management plans a domestic launch for tricuspid patients alongside a presentation of trial results; evidence of adoption would indicate whether the mitral and tricuspid franchise is beginning to carry more weight beside the much larger transcatheter valve business.
The scheduled earnings release warrants attention across revenue, gross margin, operating margin and cash conversion. Continued sales growth with operating margin holding up despite hedge-related pressure, plus operating cash flow comfortably above capital spending, would support the current pattern; deterioration across those measures would break it. Longer-range estimates also embed continued revenue and earnings expansion, raising the importance of adoption and margin execution.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Edwards Lifesciences compare with its peers?
Short answer
Edwards Lifesciences's score ranks tied for 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Edwards differs from broad medical-device groups through its narrow structural-heart focus: catheter-delivered valves are the core, surgical valves remain meaningful, and mitral and tricuspid therapies are a smaller expansion platform. That concentration supports deep clinical and commercial specialization but leaves less internal diversification when the main valve franchise slows.
Research spending is large and persistent, while gross and operating margins remain substantial and net cash provides funding flexibility. The resulting profile is closer to a focused innovation franchise than a diversified hospital-supply company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| Edwards Lifesciences (EW) — this page | $105.23 | $60.5B | 93 |
| $82.52 Nov 18, 2026 | $30.8B | 93 5-pillar Nov 18, 2026 | |
| $278.35 Nov 18, 2026 | $64.3B | 88 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $100.72 Nov 18, 2026 | $129B | 81 5-pillar Nov 18, 2026 | |
| $75.23 Nov 18, 2026 | $36.1B | 80 5-pillar Nov 18, 2026 | |
| $318.15 Nov 18, 2026 | $121B | 80 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.81 Nov 18, 2026 | $29.1B | 78 5-pillar Nov 18, 2026 | |
| $43.64 Nov 18, 2026 | $63.3B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $100.00 – $120.00
- Consensus target
- $108.70
- Median target
- $110.00
Consensus record · Captured .
Measured against a quoted price of $105.23 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 13, 2026
- Transactions
- 53
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 20
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held EW in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.15% | $35.22M | Added +48.2% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Edwards Lifesciences (EW)?
Common Questions About EW (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Edwards Lifesciences sell through its transcatheter heart valve franchise?
It supplies minimally invasive valve-replacement systems to healthcare providers. Because this franchise supplies most reported segment revenue, procedure adoption here has the greatest influence on companywide sales.
Why is PASCAL important to Edwards Lifesciences?
PASCAL extends Edwards beyond its core transcatheter valve-replacement franchise into mitral and tricuspid therapy. Management has tied the program’s near-term progress to a domestic tricuspid launch and a trial-results presentation.
Can Edwards Lifesciences expand operating margin while gross margin is pressured by currency hedges?
Management’s outlook pairs lower-end gross-margin expectations caused by foreign exchange through hedging with upper-end operating-margin expectations. Delivery therefore requires sufficient operating leverage or spending control below gross profit to absorb that pressure.
How exposed is Edwards Lifesciences to transcatheter heart valve demand?
That franchise is the largest reported revenue pool by far, ahead of surgical valves and mitral and tricuspid therapies. Demand weakness there would be difficult for the smaller franchises to offset over a short period.
What is the EW stock price today?
The last price recorded for Edwards Lifesciences Corporation (EW), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the EW price target?
The analyst consensus price target for Edwards Lifesciences Corporation (EW), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 41 figures on this page — 34 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold EW
Funds in our ETF coverage that list EW among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | 5.26% | |
| FFLS ETF | 3.76% |